Fusion polypeptide comprising a foreign antigen and self antigen
US12049484B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2023 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Mar 20, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/112
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.